
Prion protein signaling induces M2 macrophage polarization and protects from lethal influenza infection in mice
Author(s) -
Junji Chida,
Hideyuki Hara,
Kimio Uchiyama,
Eiki Takahashi,
Hironori Miyata,
Hidetaka Kosako,
Y. Tomioka,
Toshihiro Ito,
Hiroyuki Horiuchi,
Haruo Matsuda,
Hiroshi Kido,
Suehiro Sakaguchi
Publication year - 2020
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1008823
Subject(s) - biology , bovine spongiform encephalopathy , monoclonal antibody , virology , macrophage polarization , macrophage , microbiology and biotechnology , in vitro , antibody , immunology , prion protein , medicine , biochemistry , disease , pathology
The cellular prion protein, PrP C , is a glycosylphosphatidylinositol anchored-membrane glycoprotein expressed most abundantly in neuronal and to a lesser extent in non-neuronal cells. Its conformational conversion into the amyloidogenic isoform in neurons is a key pathogenic event in prion diseases, including Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. However, the normal functions of PrP C remain largely unknown, particularly in non-neuronal cells. Here we show that stimulation of PrP C with anti-PrP monoclonal antibodies (mAbs) protected mice from lethal infection with influenza A viruses (IAVs), with abundant accumulation of anti-inflammatory M2 macrophages with activated Src family kinases (SFKs) in infected lungs. A SFK inhibitor dasatinib inhibited M2 macrophage accumulation in IAV-infected lungs after treatment with anti-PrP mAbs and abolished the anti-PrP mAb-induced protective activity against lethal influenza infection in mice. We also show that stimulation of PrP C with anti-PrP mAbs induced M2 polarization in peritoneal macrophages through SFK activation in vitro and in vivo . These results indicate that PrP C could activate SFK in macrophages and induce macrophage polarization to an anti-inflammatory M2 phenotype after stimulation with anti-PrP mAbs, thereby eliciting protective activity against lethal infection with IAVs in mice after treatment with anti-PrP mAbs. These results also highlight PrP C as a novel therapeutic target for IAV infection.